These answers draw in part from “CEU: Psychopharmacology - Module 6: Ethics of Medication” (Special Learning), and extend it with peer-reviewed research from our library of 27,900+ ABA research articles. Clinical framing, BACB ethics code references, and cross-links below are synthesized by Behaviorist Book Club.
View the original presentation →The BCBA should avoid offering a personal opinion about medication and instead support the caregiver's decision-making process. Share objective behavioral data showing the child's current progress and trajectory. Help the caregiver formulate specific questions to ask the prescribing physician, such as what improvements to expect, potential side effects, and how long before effects should be visible. Offer to share behavioral data directly with the prescriber if the caregiver provides consent. This approach keeps you within your scope of competence under Code 2.01 while ensuring the caregiver has the information they need to make an informed decision with their medical team.
Implement a structured monitoring protocol that begins before the medication change occurs. Establish baselines across primary treatment targets and broader behavioral indicators including activity level, emotional responsivity, appetite, and social engagement. Mark the medication change date clearly on all data graphs using a phase change line. Continue collecting data at the same frequency and using the same measurement procedures to allow valid comparison. Use visual analysis to examine level, trend, and variability changes in the data. Document any behavioral observations that may relate to medication effects with specific descriptions rather than interpretive labels. Share findings with the treatment team at regular intervals.
The four principles are autonomy, beneficence, nonmaleficence, and justice. Autonomy requires respecting the decision-making rights of the patient and family, seeking the child's assent when possible. Beneficence obligates practitioners to act in the child's best interest, ensuring medication serves therapeutic rather than convenience-driven goals. Nonmaleficence demands that the potential harms of medication, including side effects and behavioral changes, are carefully weighed against potential benefits. Justice requires equitable access to appropriate pharmacological treatment regardless of race, socioeconomic status, or cultural background, while also addressing disparities in prescribing patterns across populations.
Several converging factors contribute to the increase. Improved diagnostic tools and greater awareness among professionals and families have led to increased identification of conditions like ADHD, anxiety, and autism spectrum disorder. The pharmaceutical industry has developed newer medications with improved safety profiles, making prescribers more comfortable recommending pharmacological intervention for younger populations. Additionally, the prevalence of trauma-related disorders in children has risen due to adverse childhood experiences, community violence, and public health crises. These factors combine to create a clinical landscape where medication is considered for a larger proportion of children than in previous decades.
The key is distinguishing between behavioral expertise and medical expertise. BCBAs are competent to discuss what behavioral data show about a client's progress, observe and report behavioral changes that coincide with medication adjustments, and support caregivers in communicating with prescribers. BCBAs should not recommend specific medications, suggest dosage changes, advise starting or stopping medication, or interpret pharmacological mechanisms. When asked questions outside your scope, acknowledge the limitation honestly and redirect to the appropriate professional. Code 2.01 is clear that practicing outside established competence boundaries is an ethical violation.
Cultural backgrounds significantly influence how families perceive psychiatric medication. Some cultures associate mental health medication with stigma or view behavioral challenges as spiritual rather than medical issues. Others may expect medication as the primary or sole intervention. Socioeconomic factors affect access to both prescribers and medication. Language barriers can prevent families from fully understanding medication information. Behavior analysts should approach these conversations with cultural humility, avoid imposing their own values, use qualified interpreters when needed, and recognize that the family's cultural context legitimately shapes their treatment preferences. Code 1.07 directs behavior analysts to actively consider cultural variables in service delivery.
If behavioral data suggest that medication is primarily producing sedation rather than therapeutic improvement, the BCBA should first document their observations systematically, including specific behavioral indicators such as excessive drowsiness, reduced engagement, and decreased responding to preferred activities. Present these observations to the treatment team factually and without accusation, framing the concern in terms of the client's quality of life and functional capacity. Reference Code 2.14 regarding least restrictive effective treatment. If the concern is not addressed through normal team communication, consider whether additional advocacy through supervisory channels or ethics consultation is warranted. Maintain a collaborative stance throughout.
Effective collaboration starts with establishing communication channels early in the treatment relationship, ideally during intake. Offer to provide the prescriber with regular behavioral data summaries in a format that is useful to them, typically brief reports with graphs rather than raw data sheets. Use medical and functional terminology rather than behavior-analytic jargon when communicating. Be responsive when prescribers request specific behavioral observations. Coordinate the timing of medication changes with behavioral intervention changes when possible to allow clearer analysis. Attend interdisciplinary team meetings when invited. Respect the prescriber's expertise while contributing your unique behavioral perspective.
Skills acquired while a client is on a psychotropic medication may be partially state-dependent, meaning they were learned under a specific physiological condition that the medication creates. If the medication is later changed or discontinued, the client may not demonstrate the same skills at the same level. This is particularly relevant for medications that significantly alter arousal, attention, or emotional state. Behavior analysts should plan for this by programming for generalization across conditions, training skills in varied states when safe and appropriate, and preparing transition plans when medication changes are anticipated. Coordinate with the prescriber about tapering schedules so behavioral supports can be adjusted proactively.
Maintain a current medication log for each client that includes medication names, dosages, prescribing physician, start dates, and any reported changes. Update this information at regular intervals by checking with caregivers. Note all medication changes on behavioral data graphs with specific dates. Document any behavioral observations that may be related to medication effects with descriptive, objective language. Record all communications with prescribers including the content shared and any recommendations received. If a caregiver reports a medication concern during a session, document both the concern and your response. This thorough documentation protects the client, supports clinical decision-making, and fulfills the behavior analyst's obligations under Code 2.12.
The ABA Clubhouse has 60+ on-demand CEUs including ethics, supervision, and clinical topics like this one. Plus a new live CEU every Wednesday.
Ready to go deeper? This course covers this topic with structured learning objectives and CEU credit.
CEU: Psychopharmacology - Module 6: Ethics of Medication — Special Learning · 2 BACB Ethics CEUs · $79
Take This Course →We extended these answers with research from our library — dig into the peer-reviewed studies behind the topic, in plain-English summaries written for BCBAs.
239 research articles with practitioner takeaways
239 research articles with practitioner takeaways
195 research articles with practitioner takeaways
2 BACB Ethics CEUs · $79 · Special Learning
Research-backed educational guide with practice recommendations
Side-by-side comparison with clinical decision framework
You earn CEUs from a dozen different places. Upload any certificate — from here, your employer, conferences, wherever — and always know exactly where you stand. Learning, Ethics, Supervision, all handled.
No credit card required. Cancel anytime.
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.